Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00355342 · ClinicalTrials.gov registry record · Phase 4

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
186
Enrollment target
20
Study locations

NCT00355342 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 186 participants, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00355342, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
186 participants
Enrollment target
20
Study locations

Study Summary

This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones. The purpose of this study is to determine the effect of the steroid component of an inhaled product on bone mineral density in patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Salmeterol 50 mcg BID
  • DRUG Fluticasone Propionate/Salmeterol 250/50 mcg BID
  • DEVICE DISKUS inhaler

Study Locations (20)

California

  • GSK Investigational Site - Berkeley
  • GSK Investigational Site - Fullerton
  • GSK Investigational Site - Rancho Mirage
  • GSK Investigational Site - San Diego
  • GSK Investigational Site - Walnut Creek

Florida

  • GSK Investigational Site - Fort Lauderdale
  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - Sarasota
  • GSK Investigational Site - Tamarac

Colorado

  • GSK Investigational Site - Fort Collins
  • GSK Investigational Site - Wheat Ridge

Illinois

  • GSK Investigational Site - Chicago
  • GSK Investigational Site - North Chicago

Connecticut

  • GSK Investigational Site - Hartford

Georgia

  • GSK Investigational Site - Atlanta

Kansas

  • GSK Investigational Site - Wichita

Massachusetts

  • GSK Investigational Site - Boston

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2004-04-28
Est. Completion 2007-09-06
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00355342

The ClinicalTrials.gov registry entry for NCT00355342 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (82% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which Salmeterol 50 mcg BID is the first listed.

NCT00355342 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT00355342 about?

NCT00355342 is a clinical study titled "Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.". This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones. The purpose of this study is to determine the effect of the steroid component of an inhaled product on bone mineral density in patients with Chronic ...

What is the current status of trial NCT00355342?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 186 participants. The study started on 2004-04-28. Estimated completion is 2007-09-06.

What conditions does trial NCT00355342 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT00355342?

The interventions under investigation include: Salmeterol 50 mcg BID (DRUG), Fluticasone Propionate/Salmeterol 250/50 mcg BID (DRUG), DISKUS inhaler (DEVICE).

Who is sponsoring clinical trial NCT00355342?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00355342 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.